{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T22:42:06Z","timestamp":1648939326437},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/maj.0b013e31820f8c70","type":"journal-article","created":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T12:29:18Z","timestamp":1299328158000},"page":"278-280","source":"Crossref","is-referenced-by-count":7,"title":["Mycobacterial Infections in the Era of Modern Biologic Agents"],"prefix":"10.1016","volume":"341","author":[{"given":"Michael D.","family":"Iseman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0005","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0010","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0015","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0020","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0025","first-page":"1","article-title":"Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/s10165-009-0226-5","article-title":"Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection","volume":"20","author":"Maeda","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0035","first-page":"776","article-title":"Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population","volume":"35","author":"Ponce de Leon","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0040","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/thx.2006.070797","article-title":"Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003","volume":"62","author":"Marras","year":"2007","journal-title":"Thorax"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0045","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1164\/rccm.200808-1258ED","article-title":"The importance of nontuberculous mycobacterial lung disease","volume":"178","author":"Iseman","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0050","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","article-title":"Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network","volume":"46","author":"Winthrop","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e31820f8c70_bb0055","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy","volume":"15","author":"Winthrop","year":"2009","journal-title":"Emerg Infect Dis"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915313173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915313173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T21:40:37Z","timestamp":1560030037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915313173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0002962915313173"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31820f8c70","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}